Plasma glial fibrillary acidic protein level in patients with Alzheimer’s disease
- VernacularTitle:血浆胶质纤维酸性蛋白水平与阿尔茨海默病的相关性研究
- Author:
Zhihong REN
1
;
Jie YU
1
;
Haili WANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Alzheimer’s disease ； Biomarkers； Glial fibrillary acidic protein
- From: Journal of Apoplexy and Nervous Diseases 2020;37(9):806-808
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the changes of plasma glial fibrillary acidic protein （GFAP） in patients with Alzheimer ’s disease （AD） and its correlation with cognitive impairment. Methods asma GFAP levels were analyzed in 34 AD patients and 38 normal controls. We investigated the differences in plasma GFAP levels between the two groups，and analyze the relationship between plasma levels of GFAP and cognitive function. Results The plasma GFAP level in the AD patients ［1253（964～1584） pg/ml］ was significantly higher than that in the normal controls ［874（698～1079）］（P<0.001）. Plasma GFAP levels might be helpful to the identification of AD from normal control with a sensitivity of 58.8% and a specificity of 86.8%. Plasma GFAP levels correlated with the mini-mental state examination （r=-0.42，P<0.001） and Montreal cognitive assessment score （r=-0.38，P<0.001）. Conclusion Plasma GFAP might be a potential biomarker in the differential diagnosis and evaluation of AD，and it is worthy of further study.
- Full text:2024073122005501524血浆胶质纤维酸性蛋白水平与阿尔茨海默病的相关性研究.pdf
